ASH2L

Across TCGA pan-cancer cohorts, ASH2L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ASH2L data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ASH2L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ASH2L expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LSCC, COAD, and HNSC are the cancer types where ASH2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	1.000	0.908	.022	12	view →
COAD	DFS	Tertile	All	1.000	0.879	.047	6	view →
HNSC	OS	Median	All	0.806	0.889	.013	6	view →
PDAC	OS	Median	II,III,IV	0.271	0.504	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ASH2L–LSCC (OS)

Open the LSCC breakdown →